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1. Introduction 
There is a strong need to obtain precise surrogate biomarkers to improve the accuracy of 
diagnosis for gliomas, and to effectively evaluate therapeutic response.  Often pre-clinical 
models of disease are used to develop diagnostic procedures and assess the effectiveness of 
a potential therapy.  For gliomas, there are a variety of rodent models that have been 
investigated by numerous investigators over the past few decades, ranging from intracranial 
rodent glioma cell implantation models, intracranial human glioma xenografts, orthotopic 
implantation of human glioma stem cells, multipotent human glioblastoma stem-like 
neurosphere lines, transgenic mouse models, to viral-induced progenitor or stem cell 
derived glioma models.  Tumor grades in these models vary from low to high grade tumors, 
with many of the high-grade glioma models sharing some of the characteristics of human 
grade IV glioblastoma multiforme (GBM).  Many of the characteristic features of gliomas can 
be assessed diagnostically with in vivo imaging techniques such as magnetic resonance 
imaging (MRI). MRI has the capability of obtaining morphological/anatomical, functional, 
biophysical, molecular and metabolic information of a disease at various pathological stages 
of development.  Tumor characteristics often associated with aggressive gliomas include an 
invasive growth pattern, angiogenesis, necrosis, hypoxia, edema, and alterations in major 
metabolic pathways.  Morphological features, such as tumor size and position, infiltrative 
growth, hemorrhaging, necrotic lesions, edema, mass effect, heterogeneity, and cyst 
formation, can be followed using standard contrast-enhanced T1-weighted MR imaging or 
non-contrast T2-weighted imaging.   
Although conventional MRI provides us with some indication about the nature of the lesion 
or tumor, it has limited sensitivity and specificity in determining histological type and 
grade, delineating margins and differentiating edema, as well as effectively evaluating 
therapeutic effects or side-effects. Incorporating some advanced MR techniques, such as MR 
angiography (MRA), perfusion-weighted MR imaging (PWI), diffusion-weighted MR 
imaging (DWI), MR spectroscopy (MRS), and molecular MRI (mMRI), may help to 
overcome some of those limitations. Angiogenesis associated with major blood vessels can 
be assessed using MR angiography, whereas perfusion-weighted imaging can be used to 
monitor angiogenesis associated with capillary vessels in tumors. Biophysical parameters 
such as water diffusion, as measured by diffusion-weighted imaging, have also provided 
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information regarding alterations in tissue structure associated with glioma tumors.  An 
extension of the diffusion-weighted imaging technique is diffusion tensor imaging (DTI), 
which can provide information on white matter neuronal fiber tractography. MR 
spectroscopy can be used to assess alterations in tumor metabolites associated with glucose, 
bioenergetics, amino acid or lipid metabolism, for example. Many of these advanced MR 
techniques are used in a clinical setting.  More recently, molecular MRI (mMRI) which 
incorporates a MRI contrast agent as a signaling molecule and an affinity component that 
targets specific tumor markers associated with tumor growth, angiogenesis, cell invasion, 
inflammation, or apoptosis, can be used to characterize in vivo molecular events associated 
with gliomas. 
This review will focus on various glioma models that have been studied in vivo, with 
particular emphasis on MR image and/or spectroscopy evaluation of these models, and the 
use of MR image criteria (morphological, biophysical, molecular and metabolic) to evaluate 
therapeutic treatments. The aims are to: (1) provide an overview on current rodent glioma 
models being studied; (2) provide an overview regarding currently used MR methods, 
including advanced MR techniques (e.g. MRA, DWI, PWI, MRS and mMRI), relevant to 
glioma research; and (3) summarize studies that have used MR methods to evaluate 
therapeutic response in pre-clinical models for gliomas.   
2. Human gliomas 
Gliomas represent 40% of all primary central nervous system (CNS) tumors diagnosed. 
Among them, glioblastomas (GBM) are the most malignant, with a very poor survival time 
of about 15 months for most patients diagnosed with this grade IV brain tumor (CBTRUS 
2011). High grade gliomas are the most common primary brain tumors in adults, and their 
malignant nature ranks them as the fourth largest cause of cancer death (Niclou et al., 2010).  
There are four tumor grades for gliomas: Grade I which is a non-malignant, fairly 
circumscribed astrocytoma that is rare and appears in young adults; Grade II which are a 
more common diffusely infiltrating astrocytoma; Grade III which is an anaplastic 
astrocytoma; and Grade IV which is a glioblastoma multiforme (Niclou et al., 2010).  Grades 
II-IV gliomas generally are found in the adult population, and often recur following current 
treatment options (including surgical resection, radiotherapy, and chemotherapy) (Niclou et 
al., 2010).  
Grading and identification criteria that can be used to provide information regarding tumor 
behavior are cell proliferation (cellularity and mitotic activity), nuclear atypia, 
neovascularization and the presence of necrosis and/or apoptotic regions (Gudinaviciene et 
al., 2004). Grade II gliomas (also referred to as diffuse astrocytomas) and grade III gliomas 
(also referred to as anaplastic astrocytomas) only differ based on their mitotic activity, and 
this difference accounts for a substantial decrease in the 5-year survival for  patients, from 
47% to 29% (from grade II to III, respectively) (CBTRUS 2011). Grade IV gliomas (GBM) are 
often characterized by the presence of large necrotic areas (Gudinaviciene et al., 2004) and 
generally have a 3% 5-year survival (CBTRUS 2011). 
3. Rodent models of gliomas 
Animal models are often used when researching a disease and trying to understand how a 
particular pathological process occurs, as well as a means of studying the efficacy of 
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potential new therapies. This review will provide examples of commonly used and new 
experimental animal models for gliomas, which make up a large portion of primary brain 
tumors.  The majority of models involve intracerebral implantation of rodent (rat or mouse) 
or human glioma cells into synergetic rats or mice, or immunocompromised rodents (e.g. 
nude or athymic rats or mice).  There are also a limited number of transgenic mouse models 
for gliomas.  One approach to better simulate a human tumor is to obtain human glioma 
neurospheres from patients during tumor resection, and then culture the cells prior to 
intracerebral implantation into immunocompromised rodents.  Another recent approach is 
to implant non-replicating viruses that can stimulate neuronal stem cells to turn into glioma 
cells which develop into diffuse tumors similar to those found in high-grade or malignant 
gliomas called, glioblastoma multiforme (or GBM). 
3.1 Intracerebral cell implantation models 
Glioma cells (rat, mouse or human origin) are injected into the cerebral cortex of rats or mice 
(synergetic if cells are transplanted into the same species and strain that they were obtained 
from, or immune-compromised rats or mice if human cells are used) using a stereotaxic 
device for precise implantation into a brain region.  As tumors grow over a period of 1-2 
months, this model is considered a short-term model. Different cell lines varying in their 
degree of malignancy, such as rat C6, 9L/LacZ, F98 and RG2 cells, mouse GL261 cells and 
human U87 cells, provide a range of gliomas from moderately aggressive to GBM-like.  
Many of these models have some characteristics associated with human gliomas, such as 
aggressive tumor growth, angiogenesis, and tumor necrosis (in a few models), however the 
diffuse nature of high-grade gliomas, glioblastoma multiforme (GBM), is not well 
represented. In many instances the intracerebrally-implanted rodent tumors have defined 
tumor boundaries, which do not represent the infiltrative nature of GBMs well. A 
comprehensive review that discusses the advantages and disadvantages of rat brain tumor 
models, most of them involving intracerebral implantation of rat glioma cells, is discussed in 
a paper by Barth and Kaur (2009).   
The rat C6 cell line produces diffusively invasive astrocytomas (Barth, 1998; Barth and Kaur, 
2009), which have been found to be similar to human glioma cells regarding the expression 
of genes mainly involved in tumor progression (Sibenaller et al., 2005). C6 gliomas were 
induced in an outbred Wistar rat strain repeatedly injected with methylnitrosourea (MNU), 
which makes it non-syngeneic in inbred strains, and increases its potential to evoke an 
alloimmune response (Barth and Kaur, 2009). As a result of some genetic similarities to 
human gliomas, the C6 model has been widely used as a GBM model for a number of years 
(Grobben et al., 2002; Barth and Kaur, 2009).  The 9L/LacZ-derived tumors are aggressive 
and infiltrative, and are angiogenic (Plate et al., 1993), which are some of the characteristics 
associated with human GBM (Weizsaecker et al., 1981). Although the aggressive 9L/LacZ 
gliomas are highly invasive (Szatmori et al., 2006) and have extensive neovascularization 
(Plate et al., 1993), due to their pronounced immunogenicity (Barth, 1998) and the fact that 
they are classified as gliosarcomas (Sibenaller et al., 2005), makes these cells a poor choice for 
glioma studies.  F98 gliomas are classified as anaplastic malignant tumors, which have an 
infiltrative pattern of growth, and also have attributes associated with human GBM (Barth, 
1998; Barth and Kaur, 2009).  The aggressive and invasive nature (Barth, 1998; Barth and 
Kaur, 2009) of RG2 tumors (Groothuis et al., 1983), as well as the highly tumorigenic human 
glioblastoma U87 MG cell line (Martens et al., 2006; Cheng et al., 1996), both mimics human 
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high-grade gliomas via inducing vascular alterations.  U87 pcDNA3 and U87 IRE1 DN 
human glioma cells were selected as malignant glioma models that form highly versus 
poorly vascularized tumors, respectively (Drogat et al., 2007; Wehbe et al., 2010). GL261 cells 
give rise to quickly growing, and diffusively invasive intracranial tumors in C57BL/6 mice 
(Szatmori et al., 2006).  RG2 and F98 glioma cell lines were both obtained from chemical 
induction as a result of administering ethylnitrosourea (ENU) to pregnant rats, where the 
progeny developed brain tumors that were isolated, and propagated and cloned in cell 
culture (Barth and Kaur, 2009).  Human U87 cells are of high interest for angiogenesis 
studies (Cheng et al., 1996).  The immunogenicity issue of the 9L/Lacz model can be 
resolved by using non-immunogenic models (e.g. RG2).   
Xenograft models, induced by orthotopic (into native tumor sites) injection of primary 
tumor cells or tumor cell lines, represent the most frequently used in vivo cancer model 
systems for glioma research (Waerzeggers et al., 2010). Both cell culture and xenograft model 
systems lack the stepwise genetic alterations that are thought to occur during tumor 
progression, and often do not represent the genetic and cellular heterogeneity of primary 
tumors, as well as the complex tumor-stroma interaction (Waerzeggers et al., 2010).  
Genetically engineered mouse models (discussed below in the “Transgenic Mouse Models” 
section) better represent the causal genetic events and subsequent in situ molecular 
evolution, the tumor-stroma interactions, and consist of cellular subpopulations such as 
cancer stem cells (discussed further in the “Human Glioma Neurospheres” and “Viral-
Induced Glioma Models” sections below), that occur in native tumors (Waerzeggers et al., 
2010). 
3.2 Chemical-induced model 
Slow-growing, low- and high-grade, spontaneous gliomas can be generated with a 
chemically-induced model from the administration of ENU (Kish et al., 2001; Koestner, 
1990). Transplacental ENU exposure of a pregnant female a day before gestation, results in 
the formation of low-grade oligodendrogliomas and mixed gliomas, with a tumor incidence 
approaching 100%, in rat pups at approximately 3-6 months of age (Koestner, 1990).  In 
addition to oligodendrogliomas and mixed gliomas, unfortunately the ENU-induced model 
also results in the formation of meningiomas (Koestner et al., 1971), spinal cord tumors 
(Koestner et al., 1971) and other primitive neuroectodermal tumors (Vaquero et al., 1992), 
decreasing its potential as a reproducible model.  In addition to the isolation of RG2 and F98 
rat glioma cells from ENU induction, A15A5 neoplastic astrocytes have also been cloned 
(Davaki and Lantos, 1980).   
3.3 Transgenic mouse models 
As we are beginning to understand the genetic mutations associated with gliomas, it is 
possible to generate transgenic mouse models that have these genetic mutations. Recent 
findings suggest that brain tumors originate from neural stem or progenitor cells.  Some 
examples of transgenic mutations include deletions of gene combinations, such as Rb/p53, 
Rb/p53/PTEN or PTEN/p53 (Jacques et al., 2010).  pRb is a retinoblastoma protein, which is 
a tumor suppressor protein that is dysfunctional in many cancers.  Rb controls excessive cell 
growth by inhibiting cell cycle progression until the cell is ready to divide (Chinnam and 
Goodrich, 2011; Lohmann, 2010). p53 which is also known as protein 53 is a tumor 
suppressor protein responsible for regulating the cell cycle (Kim et al., 2011; Maclaine and 
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Hupp, 2011; Muller et al., 2011). PTEN, which stands for phosphatase and tensin homolog, 
is a tumor suppressor gene also involved in the regulation of the cell cycle (Natsume et al., 
2011; Alexiou and Voulgaris, 2010).  Rb/p53 mice developed malignant tumors in 
approximately 9 months (Jacques et al., 2010).  PTEN/Rb/p53 tumors had an appearance 
that was similar to the Rb/p53 tumors (Jacques et al., 2010). Deletion of Rb/p53 or 
Rb/p53/PTEN resulted in the formation of primitive neuroectodermal tumors (PNET), 
which alludes to the role of an initial Rb loss involved in driving the PNET phenotype 
(Jacques et al., 2010). It was found that targeted deletion of PTEN and p53 in subventricular 
zone (SVZ) stem cells resulted in glioma formation with a latency period of approximately 
7-8 months (Jacques et al., 2010).  The tumors from the recombination of PTEN/p53 were 
histologically infiltrative, diffuse, necrotic and had signs of micro-vascular proliferation, 
which are all characteristics of human high-grade gliomas (Jacques et al., 2010).  
Another successful transgenic mouse model involves the deletion of the TP53 (tumor 
protein 53) gene (Trp53 null background), and over-expressing human PDGF (platelet-
derived growth factor) under the control of the GFAP (glial fibrillary acidic protein) 
promoter, which developed tumors with human glioblastoma-like features and with the 
integrated development of PDGFRǂ+ tumor cells and PDGFRǃ+ Nestin+ vasculature in 2-6 
months (Hede et al., 2009).  The tumor suppressor gene TP53 is either lost or commonly 
mutated in astrocytic brain tumors, and these TP53 alterations are often combined with 
excessive growth factor signaling via the PDGF/PDGFRǂ complex (Hede et al., 2009).  PDGF 
is one of many growth factors that regulate cell growth and division, and has been found to 
be widely associated with malignant gliomas (Calzolari and Malatesta, 2010; Shih and 
Holland, 2006).  
4. Human glioma neurospheres 
GBM cancer-initiating cells have been found to mediate resistance to chemotherapy and 
radiation treatment, both used as follow-up therapies following surgical resection of the 
main tumor mass (Wei et al., 2010).  Cells isolated from GBM that possess the capacity for 
self-renewal following radiation and chemotherapy, can form neurospheres when cultured 
in vitro (Wei et al., 2010).  The glioma-associated cancer-initiating cells were found to express 
MHC-I (major histocompatibility I) but not MHC-II, CD-40 or CD80, which induces T-cell 
immune deficiency, and express the costimulatory inhibitory molecule, B7-H1, which plays 
a role in mediating immune resistance in gliomas and induces T-cell apoptosis (Wei et al., 
2010). These neurospheres can be intracerebrally implanted into immune-compromised 
rodents to develop tumors in vivo, and therefore provide an experimental model that more 
closely resembles recurrent human GBM (radiation and chemotherapeutic resistant and 
induce immunosuppression) to evaluate new therapies.  Another approach that takes into 
consideration the role of tumor-initiating stem cells, is to orthotopically implant tiny 
fragments of surgically-resected tumors, containing brain tumor stem cells within the 
glioblastoma tissue, into immunocompromised mice (xenograft model) brains with the use 
of a trocar system (Fei et al., 2010).   
4.1 Viral-induced glioma models 
Glial progenitor cells in the white matter and subventricular zone within the central nervous 
system were recently found to be the likely candidates for glioma-initiating cells (Assanah et 
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al., 2006, 2009; Masui et al., 2010).  Intracerebral implantation of PDGFB-green fluorescent 
protein (GFP)-expressing retroviruses into rodents were found to induce tumors that closely 
resembled diffuse human malignant gliomas which have been challenging to treat (Assanah 
et al., 2006; Masui et al., 2010).  This model involves the use of a viral vector that stimulates 
neuronal stem cells to become glioma cells by expressing PDGF, which is involved in 
generating tumor cells (Masui et al., 2010). These studies demonstrate that both adult white 
matter and glial progenitors generate gliomas, as well as recruit resident progenitors to 
proliferate within the mitogenic environment of a tumor, and therefore contributing to the 
heterogeneous mass of cells that make up a malignant glioma (Assanah et al., 2006; Masui et 
al., 2010).  It was previously demonstrated that PDGF-B could play a dose-dependent role in 
glial tumorigenesis, where PDGFR (PDGF receptor) signaling via elevating levels of PDGF-B 
chain expression quantitatively regulates tumor grade, and that PDGF-B expression  is 
required to sustain high-grade oligodendrogliomas (Shih et al., 2004).  PDGF-B expression in 
tumor cells was elevated by removing inhibitory regulatory elements in the PDGFB mRNA 
and a retroviral delivery system (Shih et al., 2004).  To generate tumors, DF1 cells transfected 
with RCAS (repeat with splice acceptor) retroviral vectors, generating a culture of virus-
producing cells, were injected intracranially into N-tva transgenic mice (Shih et al., 2004). By 
inhibiting PDGFR activity, it was possible to convert tumors from high to low grade (Shih et 
al., 2004).   
Another recent study involved intracranial injection of lentiviral vectors with GFAP (glial 
fibrially acidic protein) or CMV (cytomegalovirus) vectors  into compound LoxP-conditional 
mice, which resulted in K-Rasv12 expression and loss of p16Ink4a/p19Arf, with or without 
concomitant loss of p53 or Pten (de Vries et al., 2010).  Like GFAP, CMV is a promoter (de 
Vries et al., 2010).  CMV-Cre injection into p53;Ink4a/Arf;K-Rasv12 mice was particularly found 
to result in the formation of high-grade gliomas within 2-3 weeks that had invasiveness and 
blood-brain barrier functionality characteristics that are found in human high-grade gliomas 
(de Vries et al., 2010).   
5. MRI methods to detect gliomas 
Magnetic resonance imaging (MRI) techniques are becoming more commonly used to 
provide information on brain tumor growth, vasculature, biochemical metabolism, and 
molecular changes in preclinical models, as MRI is the optimal imaging tool as part of the 
diagnostic process for human gliomas.  Conventional MRI techniques, such as T1- and T2-
weighted imaging, contrast-enhanced T1-weighted imaging, dynamic contrast enhanced 
(DCE) imaging, and diffusion-weighted imaging (DWI) methods can provide useful 
information on tumor location and extent of growth, blood-brain barrier (BBB) disruption, 
brain invasiveness, regional blood flow and blood volume, and tumor cellularity, all of 
which are characteristics associated with glioma grade and prognosis in a clinical setting 
(Waerzeggers et al., 2010).   
Morphological MRI (T2-weighted or T1-weighted contrast-enhanced imaging) is used to 
provide information on tumor volumes and growth rates, which can be used to distinguish 
between tumor grades.  Contrast-enhanced imaging can be used to assesses BBB disruption, 
however this feature can be absent in diffuse infiltrative tumor regions or when assessing 
therapeutic treatment (Waerzeggers et al., 2010).  DCE imaging can be used to follow tumor 
angiogenesis by measuring changes in tumor vascular permeability, vascular density and 
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vessel morphology (Waerzeggers et al., 2010), particularly regarding the capillary bed.  
Magnetic resonance angiography (MRA) is also used to provide information on tumor 
vasculature associated with angiogenesis, however it tends to be restricted to major blood 
vessels >50 microns in diameter (Doblas et al., 2010).  DWI has been used in cancer imaging 
to evaluate tumor cellularity and infiltration, as well as monitor therapeutic response 
(Kauppinen, 2002). Metabolic information can be obtained by monitoring tumor metabolites 
by a method called MR spectroscopy (MRS), or variations thereof, such as MR spectroscopic 
imaging (MRSI) or chemical shift imaging (CSI).  Molecular alterations can be assessed with 
the use of targeting MR contrast agents which can specifically indicate levels of cancer 
biomarkers that may be elevated in malignant tumors.  The development of targeted 
imaging ligands attached to MRI contrast agents allows the in vivo evaluation of tumor 
biology, such as tumor cell apoptosis, angiogenic blood vessels or the expression of specific 
tumor antigens or signaling pathways (Waerzeggers et al., 2010). 
5.1 Tumor morphology 
MRI is obtained on small animal MR imaging systems (7 - 11.7 Tesla), that can 
accommodate rodents such as mice and rats.  MR images are obtained in multiple slices 
(0.5-1 mm thick) to visualize an entire tumor (Gartesier et al., 2010).  Examples of rodent 
tumor models for gliomas  (e.g. rat C6 and RG2 models,  and mouse GL261 model)  are  
shown  in  Figure 1, depicting heterogeneous tumors (right cerebral cortex, upper regions) 
following intracerebral (orthotopic) implantation of rat or mouse glioma cells (Doblas et 
al., 2010). 
From the multiple image slices through a tumor, tumor volumes can be measured, and the 
growth rate can be calculated from multiple imaging sessions over several days, weeks or 
months (as shown in Figure 2).  Tumor areas are traced in multiple slices to calculate tumor 
volumes, which can be used to determine tumor growth and doubling times (Doblas et al., 
2008, 2010; Garteiser et al., 2010). Robust tumor volume determinations can be made by 
using manual or automated segmentation techniques, which can be used to delineate tumor 
margins on the basis of signal intensity differences from surrounding brain tissue (Waldman 
et al., 2009). 
 
 
Fig. 1. MR images of rodent gliomas. T2-weighted images of the rat C6 (A; 18 days following 
intracerebral implantation of cells) and RG2 (B; 13 days following cell implantation), and the 
mouse GL261 (C; 26 days following cell implantation) glioma models. Tumors appear as 
heterogeneous regions in the upper right area of the cerebral cortex regions.  
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Fig. 2. MR images used to calculate tumor volumes and tumor growth.  T2-weighted images 
of a mouse GL261 glioma at 14 (A), 23 (B) and 26 days (C) following intracerebral 
implantation of cells.  Tumors are outlined (white ellipses). (D) Calculated GL261 tumor 
volumes which follow an exponential increase over time. 
 
 
Fig. 3. Determination of necrotic volumes from MR image-observed tumors.  (A) T2-
weighted MR image of a GL261 mouse glioma at 23 days following intracerebral 
implantation of cells. Note dark void regions in the heterogeneous tumor which are necrotic 
lesions. (B) Necrotic volumes from tumors can be measured (n=5; meanS.D.). (C) 
Corresponding histological slide depicting necrosis in a GL261 tumor. 
Tumor morphology can also provide information on tumor invasiveness and necrotic 
lesions.  Necrotic lesions are depicted as dark void regions in a tumor (as shown in Fig. 3A), 
of which volumes (e.g. Fig. 3B) can be measured from multiple slices (Towner et al., 2010a). 
A comparison between the orthotopic rat glioma models, C6 and RG2, and the chemical 
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ENU-induced model, indicated that percent necrosis was highest in the ENU model, 
compared to RG2, and least in the C6 model (Towner et al., 2010a). Although the ENU-
induced model is used to generate low-grade gliomas, it generates a heterogeneous 
population of glioma cells ranging from low- to high-grade, which contributes to the high 
incidence of necrotic lesions (Towner et al., 2010a). RG2 gliomas are known to be more 
aggressive, invasive and infiltrative than C6 gliomas (Groothuis et al., 1983). It has also been 
shown that RG2 gliomas have more diffuse margins at the interface to adjacent brain tissue, 
whereas C6 gliomas are less infiltrative with a distinct peritumoral region at the margin of 
the tumor (Doblas et al., 2010). 
5.2 Tumor vasculature and ultrastructure 
MR angiography can provide information on new blood vessels formed in tumors, a process 
known as angiogenesis which is required to maintain tumor growth.   On small animal 
imaging MRI systems, the image in-plane resolution is >50 µm, which allows visualization 
of major blood vessels, arterioles and venules (Doblas et al., 2008, 2010). Quantitation of 
brain and tumor blood vessels can also be obtained, as well as measurements on blood 
vessel diameters and lengths (Doblas et al., 2008, 2010).   An increase in total brain tumor 
blood volume was found to directly correlate with increasing tumor volumes during tumor 
growth (Doblas et al., 2010).  
Quantification of the Brownian motion of water or diffusion within tissues can be measured 
through the apparent diffusion coefficient (ADC) which is obtained from diffusion-weighted 
imaging datasets.  DWI yields ultrastructural information on cellular density and the 
extracellular matrix (Waldman et al., 2009; Sadeghi et al., 2003). Figure 5 shows an example 
of an ADC (Fig. 5 b) map in a C6 glioma-bearing rat brain, indicating higher ADC values in 
tumor tissue compared to contralateral ‘normal’ brain tissue (Garteiser et al., 2010).   
Temporal diffusion spectroscopy based on oscillating gradient spin-echo (OGSE) MRI was 
used  to detect microscopic structural  variations at the subcellular scale in C6 rat  gliomas 
 
 
Fig. 4. MR angiography of a GL261 mouse glioma. (A) T2-weighted MR image of a GL261 
glioma-bearing mouse brain (23 days following intracerebral implantation of cells.) (B) and 
(C), 3 dimensional angiograms of mouse brain blood vessels of a GL261 glioma-bearing 
mouse.  Note altered vasculature on left-hand side in image B, as well as increased blood 
vessels (middle cerebral artery; depicted in left-mid-region of image C) in the tumor region.  
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Fig. 5. Diffusion- and perfusion-weighted imaging of a rat C6 glioma.  (A) T2-weighted MR 
image of a C6 glioma-bearing rat brain (20 days following intracerebral implantation of 
cells).  (B) ADC map (110-4 mm2/s) of a C6 glioma.  Note higher ADC values in the tumor 
compared to ‘normal’ brain tissue.  (C) Perfusion map (ml/(100gmin)) in a C6 glioma. Note 
decreased perfusion values in tumor tissue, compared to ‘normal’ brain tissue. 
(Colvin et al., 2008).  An extension of DWI is diffusion tensor imaging (DTI) which obtains 
multidirectional images that can be used to obtain diffusional directionality information 
quantified as fractional anisotropy and displayed as dominant white fiber tract maps 
(tractography) ((Waldman et al., 2009).  DTI was used to differentiate between two rat 
glioma models, which observed C6 glioma-induced ischemia of tumor-surrounding tissues, 
compared to the more infiltrative nature of F98 gliomas that penetrated into the corpus 
callosum (Asanuma et al., 2008a, 2008b). 
Arterial spin labeling (ASL), a perfusion-weighted MRI method, uses a MR image signal 
based on the influx of magnetically labeled water into blood, as a means of quantifying 
absolute levels of cerebral blood flow (CBF) (Waldman et al., 2009). Another widely used 
perfusion method is dynamic susceptibility contrast MRI (DSC-MRI), which can be used to 
measure relative cerebral blood volume, relative cerebral blood flow (rCBF) and mean 
transit time from the kinetics resulting from a change in signal intensity following the bolus 
administration of a gadolinium (Gd)-based contrast agent (Waldman et al., 2009).  Steady-
state susceptibility contrast (SSC) images were used to obtain MRI vessel caliber index (VCI) 
measurements in a xenograft orthotopic U87 mouse brain tumor model, and were found to 
correlate closely with intravital optical microscopy (IVM) measurements (Farrar et al., 2010). 
Dynamic contrast-enhanced MRI (DCE-MRI) is commonly used to measure the permeability 
of the blood-brain-barrier (BBB).  The transfer coefficient, Ktrans is associated with endothelial 
permeability, vascular surface area and blood flow ((Waldman et al., 2009). DCE-MRI 
revealed a significant change in tumor vessel permeability that was dependent on tumor 
progression and size in a GL26 orthotopic mouse glioblastoma model (Veeravagu et al., 
2008).  Fig. 5C depicts decreased perfusion values in a C6 glioma, compared to contralateral 
‘normal’ brain tissue, obtained using the ASL method.  Perfusion values were found to be 
increased in the more aggressive RG2 rat glioma compared to C6 (Towner et al., 2010a), 
which is associated with increased vascular proliferation in this model. The increased 
perfusion in the RG2 model was also correlated with increased capillary vascularity 
visualized in 3D confocal microscopy fluorescence images, as well as more diffuse and 
smaller blood vessels observed by MRA, compared to the C6 model (Towner et al., 2010a). A 
study by Valable et al. demonstrated that there was a slight reduction in vessel density in the 
tumor center within RG2 gliomas compared to a more increased reduction in vessel density 
within C6 gliomas, which was characterized by an increased blood volume fraction, and a 
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smaller relative increase in vessel size index in the RG2 tumor (Valable et al., 2008). The 
vessel density eventually decreased with increasing tumor cell proliferation (Valable et al., 
2008). It was thought that early expression of Ang-2, MMP-2 and MMP-9, which has been 
found in C6 gliomas, could account for the destabilization of vessel walls and a reduction in 
vessel density during C6 tumor growth (Valable et al., 2008). 
5.3 Tumor metabolism 
Magnetic resonance spectroscopy (MRS) is an MR method that allows regional metabolite 
levels to be measured in tumors compared to surrounding non-tumor tissue. Important 
metabolites that can be assessed by 1H-MRS in brain tumors include N-acetyl aspartate (NAA), 
total creatine (tCr), total choline (tCho), lactate, myo-inositol and mobile lipids associated with 
necrosis.  Metabolite levels can be quantified as metabolite ratios or absolute concentrations, or 
analyzed using pattern recognition (Waldman et al., 2009).  Figure 6 depicts an example of 
regional MR spectra obtained in a rat C6 glioma within tumor and contralateral ‘normal’ brain 
tissues. Glioma tissue has characteristic increased mobile lipid signals at 1.3 and 0.9 ppm, as 
well as decreased NAA, tCr and tCho, compared to surrounding ‘normal’ brain tissue.  
Metabolites measured by MRS can provide information on brain tissue status, such as (1) NAA 
being a marker of healthy neuronal integrity, which is compromised within brain tumors, (2) 
choline-containing compounds being associated with cell membrane turnover, (3) creatine-
containing compounds being associated with the cellular energy status, (4) lactate being linked 
to anaerobic respiration, and (5) mobile lipids resulting from intracellular lipid droplets and 
necrosis (Waldman et al., 2009).  Spatially resolved 1H-MRS was used to reveal significantly 
decreased levels of NAA and tCr and increased lactate (or lipids) in intracerebral rat C6 
gliomas, compared to the contralateral hemisphere (Ross et al., 1992; Terpstra et al., 1996). In 
F98 rat gliomas there were detected increases in tCho, myo-inositol and lipids, as well as the 
absence of a NAA signal (Gyngell et al., 1994).  
 
 
Fig. 6. MR spectroscopy of a rat C6 glioma.  Regional (PRESS; point-resolved spectroscopy; 
333 mm3 or 27 µl volume) was obtained in tumor (right region in T2-weighted; bottom 
spectrum) and ‘normal’ (left region; top spectrum) brain tissues (19 days post-intracerebral 
implantation of C6 cells). Peak assignments: (1) tCho (total choline), (2) tCr (total creatine), 
(3) NAA (N-acetyl aspartate), (4) methylene (-CH2-)n lipid hydrogens, and (5) methyl (-CH3) 
lipid hydrogens. 
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Other atomic nuclei, other than 1H, have also been used to assess 13C and 19F containing 
compounds in rodent gliomas.  Hyperpolarized 13C MR metabolic imaging was used to 
follow the metabolism of hyperpolarized [1-(13)C]-pyruvate to lactate in rats with human 
glioblastoma xenografts (U-251 MG and U-87 MG), indicating higher levels in tumor versus 
normal brain tissue, and variations between tumor models (Park et al., 2010). Rat 9L glioma 
cells labeled with perfluoro-15-crown-5-ether ex vivo and implanted into rat striatum was 
used to measure intracellular partial pressure of oxygen (pO2) (oximetry) in tumors 
(Kadayakkara et al., 2010).  
5.4 Molecular imaging 
The concept used in molecular imaging is to couple a targeting moiety (antibody or peptide 
targeted to a protein of interest) to a reporter molecule, such as a MRI contrast agent.  Two 
commonly used MRI contrast agents are gadolinium (Gd)-based compounds, or iron oxide-
based nanoparticles. The targeted MR probes are often injected via a tail-vein in rats or mice.  
The expression of cell adhesion molecules, such as integrins, has been found to be up-
regulated during tumor growth and angiogenesis, and ǂVǃ3 expression which has been 
correlated with tumor aggressiveness, can be measured by MRI with targeted paramagnetic-
labeled cyclic arginine-glycine-aspartic acid (RGD) peptides (Sipkins et al., 1998; 
Waerzeggers et al., 2010).  Within U87MG xenograft tumors in nude mice, RGD-labeled 
ultrasmall superparamagnetic iron oxide (USPIO) probes were found to accumulate only 
within the neovasculature associated with tumors, but not within tumor cells (Kiessling et 
al., 2009).  Tumor angiogenesis was also monitored via the expression of CD105 in F98 
tumor-bearing rats with the use of Gd-DTPA liposomes targeted to CD105 (CD105-Gd-SLs) 
and MR imaging (Zhang et al., 2009).   Combined MRI-coupled fluorescence tomography 
was used to assess epidermal growth factor receptor (EGFR) status in high- and low-EGFR 
expression tumor cells injected into nude mice by measuring the levels of a near-infrared 
fluorophore bound to a EGF ligand (Davis et al., 2010). 
MR imaging probes have also been developed to monitor in vivo levels of other angiogenic 
proteins known to be over-expressed in malignant brain tumors, such as VEGF-R2 (vascular 
endothelial growth factor receptor 2) (He et al., 2010; Towner et al., 2010b); a tumor cell 
migration/invasion marker, such as c-Met, a tyrosine kinase receptor for the scatter factor 
(also known as the hepatocyte growth factor) (Towner et al., 2008, 2010c); and the 
inflammatory marker, inducible nitric oxide synthase (iNOS) (Towner et al., 2010a).  With 
the use of a Gd-DTPA-albumin-anti-VEGFR2-biotin probe, regional differences in VEGFR2 
levels were detected by MRI in vivo in a C6 glioma model, and probe-specificity for glioma 
tissue, particularly in the peri-tumor and peri-necrotic regions, was confirmed by tagging 
the biotin moiety of the probe in excised tissues with streptavidin-Cy3 (He et al., 2010).  The 
control non-specific probe had rat IgG conjugated to the albumin, instead of the VEGFR2 
antibody.  A similar result was obtained when an aminated dextran-coated iron-oxide 
nanoparticles conjugated with a VEGFR2 antibody was used in a C6 glioma model, where 
distribution of the probe was mainly in the peri-tumor and peri-necrotic regions of the 
tumor (He et al., 2010).  Confirmation of the presence of the nanoprobes was obtained by 
using Prussian blue stain for the VEGFR2-targeting iron oxide nanoparticles in excised 
tumor tissues (He et al., 2010).   
Both Gd- and iron oxide-based probes were also developed to characterize c-Met levels in 
C6 gliomas.  c-Met is a tumor marker that is over-expressed in many malignant cancers, 
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indicative of the invasive nature of a tumor. The distribution of c-Met was found to be more 
widely dispersed, but mainly concentrated in peri-tumor regions (Towner et al., 2008, 2010c). 
Figure 7A depicts the contrast-enhancement in a C6 glioma 3 hours following i.v. 
administration of a Gd-DTPA-albumin-anti-c-Met-biotin probe, and the corresponding 
perfusion map showing the increased uptake of the anti-c-Met probe in the peri-tumor 
regions (Towner et al., 2008).   
iNOS levels were found to vary in different rat glioma models, as detected with a Gd-
DTPA-albumin-anti-iNOS-biotin (anti-iNOS) probe, where percent MRI signal intensity 
changes were highest in the C6 tumor, compared to the RG2 and ENU-induced tumors 
(Towner et al., 2010a). Dynamic kinetic monitoring of the anti-iNOS probe indicated 
sustained uptake over 3 hours within tumor tissue regions, and no specific uptake of a 
control Gd-DTPA-albumin-IgG-biotin contrast agent within tumors (Towner et al., 2010a). 
Fluorescence imaging of the anti-iNOS probe by targeting the biotin moiety with 
streptavidin-Cy3, verified higher levels of probe uptake in C6 tumors versus RG2 gliomas, 
despite the increased perfusion and micro-vascularity detected in the RG2 tumors (Towner 
et al., 2010a).  Confirmation of the presence of iNOS in glioma cell membrane, but not in  
normal astrocytes, was obtained by transmission electron microscopy of gold-labeled anti-
iNOS antibodies (Towner et al., 2010a). 
 
 
Fig. 7. Molecular MR imaging of c-Met levels in a rat C6 glioma. (A) T1-weighted MR image 
3 hours following i.v. administration of a Gd-DTPA-albumin-anti-c-Met-biotin probe. Note 
contrast enhancement in peri-tumor regions. (B) Perfusion map depicting distribution of the 
anti-c-Met probe.  (C) Illustration of the Gd-DTPA-albumin-anti-c-Met-biotin probe, with 
the antibody (Ab) conjugated to albumin. 
6. MRI evaluation of therapeutics against gliomas 
Clinically, therapeutic response to surgical resection of gliomas, followed by radiation and 
chemotherapy, can be assessed by dynamic contrast-enhanced morphological MRI, 
increases in ADC values detected by DWI (Waerzeggers et al., 2010), decreases in the 
fractional tumor volume with a corresponding low relative cerebral blood volume detected 
by perfusion imaging, and/or reduced choline levels detected by MRS (Waldman et al., 
2009).  DCE-MRI was used to establish reduced Gd enhancement consistent with decreased 
vascular permeability following i.v. bevacizumab and carboplatin therapy in a human 
glioma (UW28) nude rat model (Jahnke et al., 2009). DCE-MRI using a high molecular 
weight contrast agent, albumin-Gd-DTPA, showed significantly increased Ktrans at the rim of 
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a VEGFR tyrosine kinase inhibitor (Vetanalib, PTK787) (anti-angiogenic) treated U251 
gliomas in rats (Ali et al., 2010).  Low-molecular-weight (Gd-DOTA; gadoterate meglumine) 
and macromolecular (P846, 3.5 kDa) MR contrast-enhanced imaging was used to assess the 
therapeutic effect of an anti-angiogenic compound, sorafenic, and microbeam radiation 
therapy in a 9L gliosarcoma model, finding that anti-angiogenic therapy decreased tumor 
vessel permeability to the macromolecular contrast agent (Lemasson et al., 2010).   Dynamic 
perfusion MRI using iron oxide nanoparticles (ferumoxytol) was used to assess the vascular 
effects of an anti-angiogenic agent versus corticosteroid (dexamethasone) treatment in a 
U87MG human glioma model in athymic rats, which found that bevacizumab significantly 
decreased the tumor blood volume and decreased permeability as determined by an 
increased time-to-peak enhancement (Varallyay et al., 2009). 
Morphological MRI, MR angiography and perfusion imaging were used to assess the 
therapeutic efficacy of nitrone-based compounds as anti-glioma agents in a rat C6 glioma 
model.  It was demonstrated that the nitrone, ǂ-phenyl-tert-butyl nitrone (PBN) was able to 
prevent and/or decrease tumor volumes (by ~60-fold, with significance, p<0.001), increase 
animal survival (>90%), and decrease total tumor blood volumes (by ~20%), in comparison 
to non-treated rats bearing C6 gliomas (Doblas et al., 2008).  Another cohort of rats were 
intracerebrally implanted with C6 glioma cells, monitored for tumor growth, and when 
tumors reached a volume of ~50 mm3 (approximately at 15 days post-intracerebral 
implantation of C6 glioma cells), PBN was administered (drinking water, 0.065% w/v) for a 
period of 25 days (Doblas et al., 2008).  In the post-tumor treatment group, PBN was found 
to increase survival (40% of the treated rats, p<0.05), and decrease tumor volumes by ~2-
fold, but was found to be non-significant (Doblas et al., 2008). Regarding post-tumor 
treatment, PBN was also found to not significantly affect blood tumor volumes, compared to 
non-treated rats (Doblas et al., 2008).  It was concluded from these studies that PBN, when 
administered prophylactically, may have an effect on angiogenesis (Doblas et al., 2008).   
Conversely, rats post-tumor treated with a PBN-derivative, OKN-007, were found to have 
significantly decreased tumor volumes (~3-fold, p<0.05), decreased the apparent diffusion 
coefficients (ADC) (~20%, p<0.05), and increased tissue perfusion rates (~60%, p<0.05) in 
tumors, compared to non-treated rats (Garteiser et al., 2010). OKN-007 was administered in 
the drinking water at 10 mg/kg/day starting when tumors had reached ~50 mm3 in volume 
(about day 15 following intracerebral implantation of rat C6 glioma cells), and continued for 
a total of 10 days (Garteiser et al., 2010). One group of rats was euthanized after the 10 day 
treatment period, and a second group was monitored for an additional 25 days following 
the treatment period (Garteiser et al., 2010). In the cohort of animals that were treated for 10 
days and then euthanized, percent survival was 100% (p<0.0001), whereas for the rats that 
were monitored for an additional 25 days the percent survival was greater than 80% 
(p<0.001) (Garteiser et al., 2010).  Morphological MRI was used to calculate tumor volumes; 
diffusion-weighted imaging (DWI) was used to measure ADC, which assesses changes in 
water diffusion due to tissue structural alterations; and perfusion-weighted MRI (pMRI) 
was used to characterize tissue perfusion rates, which can provide information on 
alterations in the vascular capillary bed. Currently, the known pharmacological effects of the 
nitrones are primarily anti-inflammatory in nature.  The parent nitrone compound, PBN, is 
known to inhibit (1) cyclooxygenase-2 (COX-2), (2) inducible nitric oxide synthase (iNOS), 
and (3) nuclear factor kappaB (NF-κB) (Floyd et al., 2008). 
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ADC values have been found to increase particularly in the early phase of anticancer 
therapies (Waerzeggers et al., 2010).  Increases in ADC were found to be a time and dose 
sensitive marker of tumor (mouse xenografts) response to radiation therapy (Larocque et al., 
2009). Contrast-enhanced MRI and DWI were used to characterize the vascular and cellular 
responses of GL261 and U87 gliomas to the tumor-vascular disrupting agent (VDA) 5,6-
dimethylxanthenone-4-acetic acid (DMXAA), which indicated significantly increased ADC 
values and the accumulation of contrast agent in treated tumors (Seshadri and Ciesielski, 
2009).  ADC and 3D T2*-weighted MRI measurements were used to validate ZD6474 
(tyrosine kinase receptor inhibitor) inhibition on tumor growth and angiogenesis in 
EGFRvIII-expressing GBM8 gliomas (Yiin et al., 2010).   
In a gene therapy-induced apoptosis (ganciclovir-treated herpes simplex thymidine kinase 
(HSV-tk) gene-transfected BT4C gliomas) study, combined DWI and 1H-MRS assessment 
was used to find interconnecting trends following therapeutic response in water diffusion 
and water-referenced concentrations of mobile lipids (Liimatainen et al., 2009).  It is thought 
that apoptosis leads to an increase in 1H-MRS detectable mobile cholesterol compounds and 
unsaturated lipids resulting from the gene therapy-induced apoptosis (Hakumäki et al., 
1999; Liimatainen et al., 2006, 2009).  Amide proton transfer (APT) MRI was recently used to 
differentiate between different glioma models (SF188/V+ glioma and 9L gliosarcoma) and 
radiation-induced necrosis, where viable glioma tissue was hyperintense and radiation 
necrosis was hypointense to isointense (Zhou et al., 2011). 
Iron oxide-based nanoparticles have recently been used as cell tracking agents, or non-
targeted or targeted drug delivery.  Magnetically-labeled cytotoxic T-cells were used as 
cellular probes and tracked by T2- and T2*-weighted MRI to differentiate glioma tissue from 
focal radiation necrosis in U-251 glioma-bearing rodents (Arbab et al., 2010).  Focused 
ultrasound, which was used to permeabilize the blood-brain barrier and increase passive 
diffusion, was found to increase the delivery of drug (1,3-bis(2-chloroethyl)-1-nitrosourea 
and iron oxide nanoparticles  that can be monitored with MRI, in a rat C6 glioma model 
(Chen et al., 2010). EGFRvIII antibody-conjugated iron oxide nanoparticles were used for 
convection-enhanced delivery and targeted therapy in glioblastoma mouse xenografts 
(U87DeltaEGFRvIII), and assessed by T2-weighted MRI (Hadjipanayis et al., 2010).  
7. Conclusions 
There are several orthotopic rodent glioma models that have been used for several decades, 
and more recent transgenic, orthotopic xenograft neurosphere- or PDGFB-expressing virus-
induced models that better reflect the genetic and stem-cell involvement in glia 
tumorigenesis.  It is important that appropriate glioma models are used that best represent 
our current knowledge of malignant glioblastomas in humans. Ideally the more recent 
models should be used if possible, however if an orthotopic syngeneic model is required, 
then the rat F98 or RG2, and mouse GL26(1) models seem to have some characteristics that 
resemble aspects of human glioblastomas, such as vascular proliferation, and aggressive and 
infiltrative tumor growth.  The human U87 MG glioma cell xenograft model in athymic 
rodents also has beneficial characteristics resembling some aspects of human GBM. 
Choosing an appropriate model is particularly important when evaluating new anti-glioma 
therapies, as these models need to consider recurrent gliomas, possibly derived from cancer 
stem cells, which are radiation- and chemotherapy-resistant, and currently reflect the poor 
prognosis of high-grade gliomas in humans.   
www.intechopen.com
 
Advances in the Biology, Imaging and Therapies for Glioblastoma 
 
266 
The evaluation of critical changes during tumorigenesis, as well as monitoring therapeutic 
responses, requires the use of appropriate imaging technologies.  The focus of this review 
has been on the use of MR imaging and spectroscopy methodologies in pre-clinical rodent 
models for gliomas, many of which translate to clinical applications.    DCE-MRI and ASL 
perfusion imaging, and MRA, can provide valuable information regarding morphological 
and dynamic alterations associated with tumor vasculature or angiogenesis.  The ADC, as 
measured by DWI, and DTI, can assess tissue structural and organizational changes that 
occur during tumor formation.  MR spectroscopy provides metabolic markers, such as 
NAA, tCr, tCho, lactate, and mobile lipids that undergo significant changes in 
concentrations during glial tumorigenesis, as a result of neuronal degradation (NAA), cell 
proliferation (tCho), anaerobic respiration (lactate), and necrosis (mobile lipids).   These 
MRI-observable changes, such as tumor ADC, rCBF, Ktrans, cerebral blood volume, and 1H-
MRS detectable metabolites, can all be important criteria to assess therapeutic efficacy.  
Molecular MRI (mMRI) is a targeted approach that can be used to assess specific tumor 
molecular markers associated with angiogenesis, apoptosis, cell migration/invasion, 
metastasis, proliferation, or inflammation. Targeted probes can also be used to deliver 
therapeutic compounds to tumors that express high levels of a specific molecular marker, 
and if these probes have a Gd-, manganese (Mn)- or iron oxide-based construct, then they 
can be monitored by MRI.    
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